000			nab a22 4500
999			_c15950 _d15950
003			PC15950
005			20210706062658.0
008			200528b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91253 _aLópez Gil, María _eCardiología
100			_91249 _aArribas Ynsaurriaga, Fernando _eCardiología
100			_92225 _aFontenla Cerezuela, Adolfo _eCardiología
245	0	0	_aCatheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). _h[artículo]
260			_bEuropean heart journal, _c2014
300			_a35(8):501-7.
500			_aFormato Vancouver: Mont L, Bisbal F, Hernández-Madrid A, Pérez-Castellano N, Viñolas X, Arenal A et al; SARA investigators. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J. 2014 Feb;35(8):501-7.
501			_aPMID: 24135832 PMC3930872
504			_aContiene 26 referencias
520			_aBackground: Catheter ablation (CA) is a highly effective therapy for the treatment of paroxysmal atrial fibrillation (AF) when compared with antiarrhythmic drug therapy (ADT). No randomized studies have compared the two strategies in persistent AF. The present randomized trial aimed to compare the effectiveness of CA vs. ADT in treating persistent AF. Methods and results: Patients with persistent AF were randomly assigned to CA or ADT (excluding patients with long-standing persistent AF). Primary endpoint at 12-month follow-up was defined as any episode of AF or atrial flutter lasting >24 h that occurred after a 3-month blanking period. Secondary endpoints were any atrial tachyarrhythmia lasting >30 s, hospitalization, and electrical cardioversion. In total, 146 patients were included (aged 55 ± 9 years, 77% male). The ADT group received class Ic (43.8%) or class III drugs (56.3%). In an intention-to-treat analysis, 69 of 98 patients (70.4%) in the CA group and 21 of 48 patients (43.7%) in the ADT group were free of the primary endpoint (P = 0.002), implying an absolute risk difference of 26.6% (95% CI 10.0-43.3) in favour of CA. The proportion of patients free of any recurrence (>30 s) was higher in the CA group than in the ADT group (60.2 vs. 29.2%; P < 0.001) and cardioversion was less frequent (34.7 vs. 50%, respectively; P = 0.018). Conclusion: Catheter ablation is superior to medical therapy for the maintenance of sinus rhythm in patients with persistent AF at 12-month follow-up.
710			_9119 _aServicio de Cardiología
856			_uhttp://europepmc.org/article/MED/24135832 _yAcceso libre
942			_2ddc _cART _n0